2024
P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Wang Z, Yang M, Chao J, Martins B, Chuang C, Shumel B, Sierka D, Carboni M, Strober B. P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study. British Journal Of Dermatology 2024, 191: i63-i64. DOI: 10.1093/bjd/ljae090.128.Peer-Reviewed Original ResearchAtopic dermatitisEpisodes of itchingTreatment satisfactionMonth 1Disease controlClinical practiceProportion of patientsPatient survey studyPercentage of patientsSustained improvementFollow-up resultsPrescribed dupilumabGeneralized estimating equationsQuality of lifePatient support programmeSingle-armDupilumabSkin symptomsBaseline surveyPatientsSupport programmesPatient satisfactionPractice guidelinesStatistical significanceMonths
2020
15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry
Bagel J, Behl A, Litman H, Medeiros R, Guo N, Lebwohl M, Strober B. 15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry. Journal Of The American Academy Of Dermatology 2020, 83: ab152. DOI: 10.1016/j.jaad.2020.06.697.Peer-Reviewed Original Research
2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, Foundation P. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal Of The American Academy Of Dermatology 2008, 58: 1031-1042. PMID: 18313171, PMCID: PMC3716382, DOI: 10.1016/j.jaad.2008.01.006.Peer-Reviewed Original Research